743 results about "Juvenile rheumatoid arthritis" patented technology

There is provided a compound exhibiting an activity of suppressing immune response with reduced adverse drug reactions, which compound is useful in the chemotherapy for preventing or treating, for example, a wide range of various autoimmune diseases including systemic erythematodes, chronic rheumatoid arthritis, Type I diabetes, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis or other disorders, or chronic inflammatory diseases, or cancers, lymphoma or leukemia, or resistance to organ or tissue transplantation or rejection against transplantation.Novel amine compounds having an S1P1 / Edg1 receptor agonist effect, possible stereoisomers or racemic bodies of the compounds, or pharmacologically acceptable salts, hydrates or solvates of the compound, the stereoisomers or the racemic bodies, or prodrugs of the compounds, the stereoisomers, the racemic bodies, the salts, the hydrates or the solvates, are provided.

The invention provides methods, uses and compositions for the treatment of juvenile rheumatoid arthritis (JRA). The invention describes methods and uses for treating JRA, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to prevent flare-ups associated with JRA. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of JRA in a subject.

The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of rheumatoid arthritis in a subject.

The invention provides application of bacteroides thetaiotaomicron in treating or preventing rheumatoid arthritis or related diseases thereof, and further provides a pharmaceutical composition, a medicine, a food and feed containing the bacteroides thetaiotaomicron. Applied to animals, the bacteroides thetaiotaomicron can be used for effectively developing an anti-inflammatory efficacy, so that the symptom of redness and swelling of joint is effectively improved and the symptom of arthritis is remarkably relieved; and the bacteroides thetaiotaomicron can be effectively used for treating or preventing rheumatoid arthritis or related diseases thereof.

A human T cell clone recognizing an antigen expressed by a synovial cell of a rheumatoid arthritis (RA) patient in HLA-DR-restricted manner is disclosed, which clone is very useful in exploring the pathogenesis of RA and developing a method for treating and preventing RA.

An objective of the present invention is to provide a therapeutic agent for treating rheumatoid arthritis, juvenile rheumatoid arthritis, macrophage activation syndrome, septicemia, and FR-β expressing leukemia, which induces apoptosis in activated macrophages and folate receptor beta (FR-β) expressing leukemia cells to specifically destroy these cells. An FR-β monoclonal antibody of the present invention is preferably an IgG-type monoclonal antibody which specifically reacts with a human-type FR-β antigen and is produced from a clone resulting from immunization with an FR-β expressing B300-19 cell. The FR-β monoclonal antibody of the present invention specifically reacts with the FR-β antigen of activated macrophages and FR-β expressing leukemia cells and a therapeutic agent of the present invention contains an FR-β antibody immunotoxin which causes apoptosis in activated macrophages and FR-β expressing leukemia cells, as an active ingredient. Further, suitable administration form for the therapeutic agent of the present invention includes intravenous injection as well as joint injection in the case of therapeutic agents for rheumatoid arthritis and juvenile arthritis.

The invention provides an application of bacteroides caccae in treatment or prevention of rheumatoid arthritis or related diseases thereof, and also provides bacteroides caccae containing pharmaceutical compositions, medicaments, foods and feeds. By providing bacteroides caccae for animals, an anti-inflammatory effect can be effectively played, the symptoms such as redness and swelling of joints are effectively improved, and the symptoms of arthritis are obviously relieved, and therefore, the bacteroides caccae can be effectively used for treating or preventing rheumatoid arthritis or related diseases thereof.

The invention encompasses novel methods of treating rheumatoid arthritis and its symptoms and novel methods of identifying and screening for drugs useful in the treatment of rheumatoid arthritis and its clinical symptoms. Targeted manipulation of a computer model of a human rheumatic joint provided the surprising result that decreasing the activity of FLIP, an inhibitor of apoptosis, by at least 25% has a significant impact on the pathophysiology of rheumatoid arthritis. Inhibition of the activity of FLIP by at least 25% is predicted to alleviate the symptoms of rheumatoid arthritis.

A Chinese medicine in the form of plaster for treating rheumatic arthritis, cervical spondylopathy, lumbar intervertebral disk protrusion, lumbar hyperosteogeny, etc is prepared from the Chinese-medicinal materials. Its advantages are simple preparing process, high curative effect, and short course of treatment.

Disclosed are compositions and methods for the treatment and / or prevention of rheumatoid arthritis, comprising administering to a subject an effective amount of anti-IL-1β antibody or fragment thereof.

The present invention relates to a method aiding in the assessment of rheumatoid arthritis. The method especially is used in the differential diagnosis of rheumatoid arthritis in vitro. The method is for example practiced by analyzing biochemical markers, comprising measuring in a sample both the concentration of anti-CCP and of antinuclear antibodies (ANA) correlating the concentrations determined to the diagnosis of rheumatoid arthritis. To further improve the assessment of RA in a method of this invention the level of one or more additional marker may be determined together with anti-CCP and ANA and be correlated to the absence or presence of RA. The invention also relates to the use of a marker panel comprising anti-CCP and ANA in the diagnosis of rheumatoid arthritis and it teaches a kit for performing the method of the invention.

Human aggrecanase and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting aggrecanase activity in a host and methods of treating disease conditions associated with aggrecanase activity, e.g. rheumatoid arthritis, osteo-arthritis, infectious arthritis, gouty arthritis, psoriatic arthritis, spondolysis, sports injury, joint trauma, pulmonary disease, fibrosis, and the like.

The invention discloses an epitope of rheumatoid arthritis and application thereof, belonging to the technical field of immunologic diagnosis. The epitope is a polypeptide, and the amino acid sequence is disclosed as SEQ ID NO:1 in the sequence table. ELISA detection and patient serum reaction condition indicate that the epitope polypeptide can be specifically combined with IgG in the patient serum, and does not react with the serum of a health person. The epitope polypeptide can be used for preparing medicines for diagnosing rheumatoid arthritis.

The invention relates to a Chinese medicinal preparation for treating rheumathritis, wherein the constituents include freeze-dried spider powder, Loranthus mulberry mistletoe, dahurian angelica root, achyranthes and cyathula root, speranskia herb, ledebouriella root, tetrandra root, Clematis chinensis, pubescent angelica root, large-leaf gentian root, notopterygium root, asarum, bark of peony root, Chinese angelica root, spatholobus stem, Ligusticum wallichii, tuber of multiflower knotweed, root of herbaceous peony, spicebush root, eucommia bark, dipsacus root, atractylodes rhizome, Chinese ephedra, frankincense, notoginseng, myrrh, safflower, epimedium, Cinnamomum cassia, cassia twig, Chinese flowering quince, red ginseng, cortex acanthopanacis, licorice root, Chinese date and white spirit.

The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.

The present invention pertains, at least in part, to substituted tetracycline compounds. The present invention also pertains to methods for treating rheumatoid arthritis in a subject, comprising administering to the subject a tetracycline compound of the invention.

The present invention relates to fusion proteins comprising an antibody, functional fragment or functional derivative thereof having specific binding affinity to either the extracellular domain of oncofetal fibronectin (ED-B) or at least one of the extracellular domains of oncofetal tenascin fused to a cytokine selected from the group consisting of IL-10, IL15, IL-24 and GM-CSF, functional fragments and functional derivatives thereof. The invention is also directed to the use of at least one of said fusion proteins for the manufacture of a medicament. In particular, the invention concerns the use of said medicament for the treatment of tumors or chronic inflammatory diseases such as atherosclerosis, arthritis and psoriasis.

It is intended to provide a transgenic nonhuman mammal well representing the pathologic conditions of human rheumatoid arthritis. A transgenic nonhuman mammal is obtained by transferring a foreign DNA, wherein a DNA selected from the group consisting of an MHC class II transcriptional activator gene, the activity domain of an MHC class II transcriptional activator gene and a variant of an MHC class II transcriptional activator gene is provided under the control of a type II collagen promoter, into a cell at the early stage of development.

The present invention provides a heterocyclic compound having a TLR7, TLR9, TLR7 / 8, TLR7 / 9 or TLR7 / 8 / 9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases, inflammatory diseases and the like, in particular, systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

The invention discloses Chinese medicinal liquor and particularly discloses Chinese medicinal liquor for treating rheumatic and rheumatoid arthritis and a preparation method thereof. The Chinese medicinal liquor for treating the rheumatic and rheumatoid arthritis is characterized by being prepared from the following components: Chinese angelica, Szechuan lovage rhizome, cassia twig, dahurian angelicaroot, incised notopterygium rhizome, divaricate saposhnikovia root, root of largeleaf gentian, clematis root, processed common monkshood mother root, processed kusnezoff monkshood root, papaya, medicinal cyathula root, tall gastrodia tuber, liquor garter snake, coix seed, safflower, fried peach seed, himalayan teasel root, turmeric, yellowmouth dutchmanspipe root, processed atraotydin, vinegar armadillo and earthworm. The Chinese medicinal liquor is specially used for treating the rheumatic and rheumatoid arthritis, has clinical application safety, treats both principal and secondary aspects of diseases, does not stimulate internal organs after being orally taken, has quick response, is safe and reliable, can make a patient have early recovery, medium-term control and late relief, and has the better effects of treating the rheumatic and rheumatoid arthritis and neck-waist-limb pain or relieving the symptoms. The Chinese medicinal liquor totally treats 580 patients, and the total effective rate reaches 97 percent.

An extract of prunella spike for treating rheumatoid arthritis and improving immune suppression contains phenolic acid (60-70%) and rosemaric acid (14-21%). Its preparing process is also disclosed.

This invention relates to a protein C1ORF32 and its variants and fragments and fusion proteins thereof, and methods of use thereof for immunotherapy, and drug development, including but not limited to as immune modulators and for immune therapy, including for autoimmune disorders.

Compounds represented by formula (I) and the formula (IV) have an inhibitory activity of MMP-9 production, therefore, are useful as a medicine agent with fewer side effects than conventional MMP enzyme activity inhibitors, as a prophylactic and therapeutic drug for oncogenic angiogenesis, chronic rheumatoid arthritis, vascular intimal thickening after a percutaneous coronary transluminal angioplasty, vascular atherosclerosis, hemorrhagic apoplexy, acute myocardial infarction, chronic heart failure, aneurysm, lung cancer metastasis, adult respiratory distress syndrome, asthma, interstitial pulmonary fibrosis, chronic rhinosinusitis, bronchitis or chronic obstructive pulmonary disease (COPD).

Provided herein is a method of treating rheumatoid arthritis using a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.

The invention relates to a Chinese medicine composite used for treating rheumatoid arthritis which belongs to the field of external applying and infusing Chinese medicine products. The technical proposal is that the composite comprises the materials according to the parts by weight as follows: 15 to 18 parts of Angelica sinensis, 15 to 18 parts of safflower, 15 to 18 parts of garden balsam stem, 15 to 18 parts of medical cyathula root, 15 to 18 parts of szechuan aconite, 15 to 18 parts of wild aconite, 10 to 18 parts of asarum, 10 to 15 parts of frankincense, 10 to 15 parts of myrrh, 15 to 20 parts of nidus vespae, 10 to 15 parts of mulberry twig, 5 to 8 parts of borneol, 10 to 15 parts of clematis root, 15 to 20 parts of pepper stem, 15 to 20 parts of astragalus root, 10 to 15 parts of rhizoma cibotii, 10 to 15 parts of heracleum hemsleyanum michaux, 10 to 15 parts of cassia twig, 10 to 15 parts of lycopodium calvatum, 10 to 15 parts of artemisia leaf, 10 to 15 parts of rhizoma ligustici wallichii and 8 to 10 parts of whole worm. The composite which is compatible with various materials has the efficacies of stimulating circulation to end stasis, relieving rigidity of muscles and activating collaterals, easing joint movement, dispersing cold and relieving pain, etc.

The invention provides nine micro RNA (Ribonucleic Acid) (miRNA) molecular markers for diagnosing rheumatoid arthritis and an application thereof to a detection kit. The miRNA molecular markers have abnormal expression in blood of patients with the rheumatoid arthritis to diagnose the rheumatoid arthritis; the miRNA molecular marker has high combination sensitivity and specificity; materials are convenient to fetch; the miRNA molecular marker is safe and noninvasive and provides important evidences to early diagnosis of diseases and disease course monitoring. The invention further provides a kit for diagnosing the rheumatoid arthritis and the application of the miRNA molecular marker to the diagnosing kit. The kit is characterized by comprising the combination of the nine miRNA molecular markers for detecting blood plasma and a reagent for detecting the nine miRNA molecular markers.

The invention relates to the field of medicines, in particular to an angiogenesis inhibitor for inhibiting several matrix metal protein enzyme and inhibiting the transfer of the vascular endothelial cell, which can be applied to preparation and treatment of entity tumor and rheumatoid arthritis. The polypeptide comprises a polypeptide I, polypeptide II, polypeptide III and polypeptide IV (Seq NO.1, Seq NO.2, Seq NO.3, Seq NO.4); The polypeptide can be used for treating entity tumor and rheumatoid arthritis. The four angiogenesis inhibitors can be applied to preparation of medicine for treating tumor, and is characterized in that: the tumor is derived from primary of neck, brain, thyroid gland, esophagus, pancreas, lung, liver, stomach, mammary gland, kidney, colon or rectum, ovary, cervix, uterus, prostate, bladder and testis or secondary cancer, melanoma, hemangioma and sarcoma.

The invention provides a medicine for treating rheumatoid arthritis and ankylosing spondylitis and its preparation method, wherein the preparation is prepared form Chinese medicinal herbs incluing multibanded krait, black-tail snake, earthworm, buthus martensi kirsch, centipede, pangolin scales, American ginseng, dragon's blood resin, notoginseng, wood louse, batryticated silkworm, apiary, deer horn gum, root of herbaceous peony, arisaema tuber, corydalis tuber, licorice root, and borneol.